FDA rejects Singulair-Claritin combination

Apr 30, 2008

The U.S. Food and Drug Administration rejected a proposed pill that would combine the drugs Claritin and Singular, Schering-Plough said.

The drug, a combination of loratadine and montelukast developed in a joint venture between Schering-Plough and Merck Pharmaceuticals, was targeted for patients with allergic rhinitis symptoms and nasal congestion.

The active ingredients of Claritin is loratadine and the active ingredient of Singulair is montelukast sodium. Both drugs are indicated for the relief of symptoms of seasonal allergic rhinitis and perennial allergic rhinitis, the two drug companies said in a statement.

The companies did not explain the FDA's reason for rejecting the drug combo.

Copyright 2008 by United Press International

Explore further: US aims to cut antibiotic use

add to favorites email to friend print save as pdf

Related Stories

Asthma drug prevents spread of breast cancer: study

Nov 03, 2010

A drug commonly used in Japan and Korea to treat asthma has been found to stop the spread of breast cancer cells traditionally resistant to chemotherapy, according to a new study led by St. Michael's pathologist Dr. Gerald ...

Munich researchers discover key allergy gene

Aug 22, 2008

Together with colleagues from the Department of Dermatology and Allergy and the Center for Allergy and Environment of the Technische Universität München, scientists at the Helmholtz Zentrum München have pinpointed a major ...

Hay fever can send work productivity down the drain

Apr 26, 2007

Employers can blame hay fever for the loss of millions of hours of work productivity this spring. A new study of nearly 600 people with hay fever symptoms, including sneezing, watery eyes and runny and itchy noses, found ...

Recommended for you

US aims to cut antibiotic use

Mar 27, 2015

US President Barack Obama on Friday rolled out plans to cut inappropriate antibiotic use by half, in an effort to tackle drug resistance.

Questions over value of new antibiotics to tackle resistance

Mar 26, 2015

In the first installment of a new series, Peter Doshi, Assistant Professor at the University of Maryland School of Pharmacy and Associate Editor at The BMJ, asks why authorities are approving drugs with little evidence they d ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.